BBIO · NASDAQ
BridgeBio Pharma (BBIO) Stock Price & Fundamentals
BridgeBio Pharma (BBIO) closed at $280.73 on Oct 9, 2026, up 0.72% from the previous close of $278.71.
Share price, past year
1Y −8.62%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $280.73 |
| Sep 30, 2026 | $273.88 |
| Aug 31, 2026 | $280.39 |
| Jul 31, 2026 | $305.47 |
| Jun 30, 2026 | $295.06 |
| May 29, 2026 | $305.82 |
| Apr 30, 2026 | $300.96 |
| Mar 31, 2026 | $288.19 |
| Feb 27, 2026 | $284.51 |
| Jan 30, 2026 | $280.24 |
| Dec 31, 2025 | $273.34 |
| Nov 28, 2025 | $284.40 |
| Oct 31, 2025 | $299.07 |
Key statistics
- Market cap
- $54.82B
- P/E (TTM)
- —
- EPS (TTM)
- −$3.57
- Revenue (TTM)
- $713.07M
- Net income (TTM)
- —
- Shares outstanding
- 195.3M
- Dividend yield
- —
- 52-week range
- $267.58 – $307.20
BridgeBio Pharma's market cap is $54.82B, based on a share price of $280.73 and 195.3M shares outstanding as of Jun 30, 2026.
Financials
BridgeBio Pharma reported revenue of $502.08M for fiscal 2025, up 126.26% from fiscal 2024.
Fiscal 2025 revenue was the highest in the 7 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $502.08M | +126.3% | — | — | −$3.78 | −$447.01M |
| FY2024ended Dec 31, 2024 | $221.90M | +2,285.3% | — | — | −$2.88 | −$521.66M |
| FY2023ended Dec 31, 2023 | $9.30M | −88.0% | — | — | −$3.95 | −$529.03M |
| FY2022ended Dec 31, 2022 | $77.65M | +11.4% | — | — | −$3.26 | −$424.32M |
| FY2021ended Dec 31, 2021 | $69.72M | +745.1% | — | — | −$3.90 | −$511.18M |
| FY2020ended Dec 31, 2020 | $8.25M | −79.7% | — | — | −$3.80 | −$407.23M |
| FY2019ended Dec 31, 2019 | $40.56M | — | — | — | −$2.48 | −$256.23M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $243.68M | — | −$0.78 |
| Q1 FY2026ended Mar 31, 2026 | $194.52M | — | −$0.84 |
| Q4 FY2025ended Dec 31, 2025 | $154.18M | — | −$1.00 |
| Q3 FY2025ended Sep 30, 2025 | $120.70M | — | −$0.95 |
| Q2 FY2025ended Jun 30, 2025 | $110.57M | — | −$0.95 |
| Q1 FY2025ended Mar 31, 2025 | $116.63M | — | −$0.88 |
| Q4 FY2024ended Dec 31, 2024 | $5.88M | — | −$1.43 |
| Q3 FY2024ended Sep 30, 2024 | $2.73M | — | −$0.86 |
Company profile
- Name
- BridgeBio Pharma, Inc.
- Ticker
- BBIO
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 3160 Porter Dr., Suite 250, Palo Alto, CA 94304
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001743881
Recent SEC filings
- Aug 31, 2026
- Aug 17, 2026
- Aug 10, 2026
- Aug 10, 2026
- Jul 22, 2026
- Jul 2, 2026
- Jun 26, 2026
- May 27, 2026
Frequently asked questions
What is BridgeBio Pharma's stock price?
BridgeBio Pharma (BBIO) closed at $280.73 on Oct 9, 2026, up 0.72% from the previous close of $278.71.
What is BridgeBio Pharma's market cap?
BridgeBio Pharma's market cap is $54.82B, based on a share price of $280.73 and 195.3M shares outstanding as of Jun 30, 2026.
How much revenue does BridgeBio Pharma make?
BridgeBio Pharma reported revenue of $502.08M for fiscal 2025, up 126.26% from fiscal 2024.
Does BridgeBio Pharma pay a dividend?
BridgeBio Pharma's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from BridgeBio Pharma, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures